A new advance in the understanding of breast cancer and a new pharmacological approach

A new advance in the understanding of breast cancer and a new pharmacological approach

The team of Pierre Close and Alain Chariot (GIGA-Molecular Biology of Diseases) from the University of Liège has identified a genetic way to block breast cancer.

Breast cancer is the most prevalent cancer in women. It would affect 1 woman on 9.

It is known that any tumor grows from genetic mutations and from changes in the cellular environment, at the level of protein expression. The step of protein production is a crucial mechanism in tumor cells adaptation and metastasis formation.

The researchers have demonstrated that the expression of ELP3 and CTU1/2 enzymes, involved in the regulation of protein synthesis, is up-regulated in human breast cancers.

In addition, they have shown that ELP3 genetic ablation strongly impaired the tumor growth in the mammary gland and its metastatic progression. Moreover, the inhibition of these enzymes significantly reduces the invasion of breast cancer cells.

A molecular dissection allowed to highlight that the various steps leading to metastasis development cannot be implemented without ELP3 and CTU1/2. Indeed, these enzymes are crucial for translating the oncogenic DEK protein that regulates the expression of LEF1 transcription factor.

The expression levels of ELP3, DEK and LEF1 are actually correlated in human mammary tumors and are associated with an increased risk of developing metastases. Therefore, the results obtained by the team of GIGA, illustrate the crucial role of this enzymatic cascade in the regulation of protein translation, in tumoral development and in metastatic progression in breast cancer.

The inhibition of these enzymes could be a new pharmacological approach for the treatment of metastatic breast tumors.

These results have been published in the “Journal of Experimental Medicine”

Related articles

PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

Liège (Belgium), 21st January 2019. PDC*line Pharma is delighted to announce, that the company is now accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for the Quality Control and Release activities of its anticancer agent PDC*lung, intended for the treatment of patients with lung cancer.  PDC*line Pharma is developing a new

Read more
PDC*line Pharma is GMP accredited by the Belgian Federal Agency for Medicines and Health Products (FAMHP) for its Quality Control and Release Activities for PDC*lung, a drug for lung cancer immunotherapy

First Congress in Health Simulation

The Medical Simulation Center of the University of Liège organizes its first congress in Health Simulation: “Towards evidence-based simulation”. Event will be held on Thursday, March 28th, 2019 in the faculty of medicine amphitheatres of Liège University, located on Sart-Tilman campus. Several themes will be discussed: Evidence-based Innovations and advances in simulation Medical education –

Read more
First Congress in Health Simulation

New University Certificate for clinical trials

The Clinical Sciences Department of the Medicine Faculty of the University of Liège organizes from the academic year 2018-2019 a University Certificate in clinical trials. More information is available in this folder

Read more
New University Certificate for clinical trials